December 11, 2008 | The media took contrasting views of Eli Lilly’s lowered financial expectations for 2009. Bloomberg said “Lilly Below-Estimate Forecast Shows Drugmaker Slump,” whereas Forbes thought “Lilly looks healthy.” The difference is largely due to whether one includes the costs of recently acquiring ImClone for $6.5 billion. Lilly also said it planned to reduce its costs of new drug development from $1.2 billion to $800 million by 2010. Read more and more.